In this write-up, we emphasize on ZAR short vs a 50:50 USD:EUR basket and shorting EURHUF through a 6m seagull:
In EM, ZAR kept showing weakness constantly against both dollar and the euro since last March 2017, however, it’s never too late, we prefer to rely on sovereign rating downgrades are an imminent risk to ZAR and expect further hedging demand and outflows in preparation for the event.
We also continue to believe a market-unfriendly outcome is more likely out of the December ANC elective conference. Initiate short ZAR as market too complacent post-MTBPS.
For HUF, the central bank clearly signaled it will announce new measures at its next meeting on November 21.
However, our EMEA strategists believe these will focus on flattening the yield curve via technical instruments without expanding the central bank balance sheet. Such step would not be effective in weakening the currency, which we also don't believe is the aim of the policy.
We, therefore, continue to believe EURHUF will retrace lower.
Sold ZAR vs an equally weighted basket of EUR and USD. Enter 15.2740, review level 15.00, target 16.10. Marked at +1.85%.
Long a 6m EURHUF put spread (strikes 304297), short a 6m 312 call. Paid 0.05% notional September 1. Marked at -0.90%.


European Stocks Rally on Chinese Growth and Mining Merger Speculation
Mega IPOs Like SpaceX and OpenAI Could Reshape S&P 500 and Nasdaq 100 Portfolios in 2026
S&P 500 Relies on Tech for Growth in Q4 2024, Says Barclays
Lithium Market Poised for Recovery Amid Supply Cuts and Rising Demand
China’s Growth Faces Structural Challenges Amid Doubts Over Data
Indonesia Surprises Markets with Interest Rate Cut Amid Currency Pressure
Gold Prices Slide as Rate Cut Prospects Diminish; Copper Gains on China Stimulus Hopes
Urban studies: Doing research when every city is different
Goldman Sachs Sees Stronger U.S. Dollar as Global Economic Gaps Widen
Cuba needs a long-term solution to its energy crisis
Global Markets React to Strong U.S. Jobs Data and Rising Yields
JPMorgan Sees Biotech Sector at Turning Point, Upgrades Top Pharma Stocks 



